Inhaled furosemide for dyspnoea relief in advanced heart failure

uffield Dept of Obstetrics and Gynaecology, University of Oxford0 个研究点目标入组 12 人开始时间: 2015年9月9日最近更新: 2022年6月27日

适应症

试验速览

暂无简介。

•1. Those unable to consent for themselves
•2. History of allergic reaction (hypersensitive) to furosemide and/or any of the other ingredients of furosemide or amiloride, sulfonamides or sulphonamide derivatives, such as sulfadiazine or co¬trimoxazole
•3. Individuals who are dehydrated or have significant symptomatic postural hypotension
•4. Significant renal impairment (eGFR <15) or anuric
•5. Significant hepatic impairment/cirrhosis (Child¬Pugh class C)
•6. Addison's disease
•7. Digitalis intoxication
•8. Porphyria
•9. Individuals who are immunocompromised
•10. Patient with life expectancy <6 months
•11. Patients who are inappropriate for saline
•12. Co-existent history of significant chronic obstructive pulmonary disease or asthma or interstitial lung disease or nasal polyps
•13. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the patients at risk because of participation in the trial, or may influence the result of the trial, or the patient’s ability to participate in the trial
•14. Have participated in another research trial involving investigational product in the past 4 weeks
•15. Patients who have had an admission to hospital with heart failure within the last 3 months
•16. Female patients who are pregnant, lactating or planning pregnancy over the course of trial

发起方

uffield Dept of Obstetrics and Gynaecology, University of Oxford